The Biotech Growth Trust used its Annual General Meeting on 16 July 2026 to set out a clear strategy for the rest of the year: remain focused on smaller biotechnology companies, back businesses with stronger clinical prospects and use current valuations to build exposure to future drug development.
Portfolio Manager Geoff Hsu said the Trust continues to favour small and mid-cap biotechnology companies over larger peers. The manager believes these businesses remain undervalued despite the sector’s recent recovery and offer greater exposure to clinical progress, takeover activity and new product approvals.
The portfolio is spread across companies at different stages of development. These include businesses running Phase II and Phase III trials as well as companies already selling approved treatments. Holdings cover oncology, immunology, cardiovascular disease and central nervous system disorders.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
